Comparative Effectiveness Research: Do Employers Care? What Will They Do? What About Productivity?

This article discusses a survey of employers, conducted by the Benfield Group and supported by the National Pharmaceutical Council, that found that one of the benefits employers are looking for from comparative effectiveness research (CER) is more information about which treatments help with productivity. While data is beginning to emerge regarding the links between good health, productivity and employee wellness programs, this survey shows that most companies (or the benefit consultants they work with) do not have access to the information or any ability to use it in their decision-making.
Specifically, while fewer than one-third of employers or their vendors currently use information about absence, disability and return to work assessing the impact of alternative treatments, 70 percent indicate that such information would be “Important” or “Very Important” within CER. And, while fewer than 25% now use information about the impact of alternative treatments on work productivity in making decisions, over 60% rate this information as “Important” or “Very Important” in CER.
In a more direct analysis of the benefit of CER to employers, respondents were asked how they would handle two specific scenarios related to treatments for low back pain and diabetes. According to the findings, employers are generally more likely to take action based on CER evidence regarding diabetes. The reasons given include the “perceived higher total costs” of treating diabetes and a belief that it would be easier to make changes to address diabetes based on “already generally accepted guidelines for treatment.”
In addition to productivity related information, additional survey findings of note include clear messages about what other types of information employers want: “clinical outcomes of alternative treatments; information comparing utilization and cost of treatments; information about which treatments work best for specific population, and; comparative safety of alternative treatments.”
Although a subscription to the JOEM is required to read this article, the full study, survey instrument and video are available on NPC's website.
CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...CER Collaborative: Providing the Tools for Better Formulary Decisions
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer
WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...NPC Survey Shows Health Care Stakeholders Continue to Show Optimism About Future Role of Comparative Effectiveness Research
(Washington, DC, March 19, 2013)—As the implementation of the Affordable Care Act (ACA) picks up speed, a new survey shows that health care...National Pharmaceutical Council Welcomes Amgen as Its Newest Member
Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards
Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...The State of CER and the Environment for Health Care Decision Making
This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...Keeping Our Eye on the CER Ball
Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...CER Collaborative: Assessing Evidence and Informing Decision-Making
National Pharmaceutical Council (NPC) Director of Comparative Effectiveness Research Dr. Jennifer Graff discusses an initiative designed to help...The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making
NPC discusses the findings from its third annual survey that gauges the attitudes and expectations of comparative effectiveness research (CER) among...Taking Patient Variations Into Account
Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...CER Collaborative: Providing the Tools for Better Formulary Decisions
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...CER Tweets of the Week (Apr. 29 – May 3, 2013)
Conversations on Twitter about evidence and comparative effectiveness research highlighted the Agency for Healthcare Research and Quality’s call for...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...Research
Principles for Planning and Conducting Comparative Effectiveness Research
A group of leading researchers developed a set of 13 best practice principles that could help to...Noncompliance with Medications: An Economic Tragedy with Important Implications for Health Care Reform, 1994
The economic and medical consequences of noncomplian
Effectiveness of Interventions to Improve Patient Compliance: A Meta-analysis
This statistical analysis of 153 studies to explore different approaches of how to improve patient...- 1 of 21
- >
Commentary & Testimony
The State of CER and the Environment for Health Care Decision Making
Keeping Our Eye on the CER Ball
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Living Up to Its Name? The Role of Patient-Centered Research
The Risks of Standardized Health Care